The Conversation (0)
Cantabio Pharmaceuticals announced the publication in a peer-reviewed journal from its CEO Dr. Gergely Toth.
Cantabio Pharmaceuticals (OTCQB:CTBO) announced the publication in a peer-reviewed journal from its CEO Dr. Gergely Toth and researchers at the University of Cambridge.
As quoted in the press release:
The article, Detection and Characterization of Small Molecule Interactions with Fibrillar Protein Aggregates using Microscale Thermophoresis, reported on a novel and general methodology for studying small molecule and protein fibril interactions and demonstrated that one of the Company’s lead Tau targeting pharmacological chaperone molecules binds to Tau fibrils with high affinity. The manuscript is available online at https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.7b00228.
Cantabio’s CEO, Gergely Toth PhD, MBA, stated, “We are pleased to publish some new data on one of Cantabio’s lead Tau targeting small molecule candidates carried out by researchers from the University of Cambridge. This study has established that our pharmacological chaperone targeting the Tau protein, a major target for Alzheimer’s drug discovery, has a strong binding affinity to its target, which further demonstrates its suitability as a potential drug candidate, and indicates that it has the potential to be developed into a Positron Emission Tomography (PET) imaging agent for the diagnosis of Alzheimer’s Disease and Dementia.”
Click here to read the full press release.
Source: www.marketwired.com
